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INTRODUCTION 
MEDICINALCHEMISTRY 
Medicinal chemistry is a chemistry based discipline, also involving aspects of 
biological, medical and pharmaceutical sciences. It is concerned with the invention discovery, 
design, identification and preparation of biologically active compounds, the study of their 
metabolism, the interpretation of their mode of action at the molecular level and construction 
of structural activity relationship.       
Medicinal chemistry involves the lead molecules potency, selectivity, reduce toxicity, 
pharmacokinetic and pharmaceutical properties. It is a science whose roots lie in all branches 
of chemistry and biology. The earlier sources of drugs were from plants, animals and mineral 
but due to the lack of potential action and definitive cure and some time more toxicity, the 
discovery of new drugs that are more potential and less toxic is essential. The synthesis of 
derivatives has been an important part and is aimed at modifying the action of drugs, 
particularly to reduce the side effects and to potentiate the drug action. Today more than 60% 
drugs used in practice are synthesized derivatives and day by day the scope of synthetic 
medicinal chemistry is broadening. 
Once of new pharmaceutical lead compound has been discovered, extensive and 
costly efforts usually are made to prepare a series of analogue in the hope that even better 
activity will be found such programs included the branching, lengthening or shortening of 
chain structure, the variation of the kinds and positions of substituent’s the replacement of 
rings by similar cyclic structures and other empirical molecular modifications within the 
frame work of reasonably close analogue. 
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TRIPHENYL IMIDAZOLE(9,19) 
                                        
N
H
N
  
Imidazoles are probably the most well known heterocycle which is common and 
important feature of a variety of natural products and medicinal agents.   
The compoundC21H16N2, has been known since 1877. Although the crystal structure 
of 36 derivatives of  lophine are known, the structure of parent compound has remained 
unknown until now.  
The three phenyl rings bonded to the imidazole core are not coplanar with the latter, 
with dihedral angles of 21.4 (3), 24.7 (3), and 39.0 (3)°, respectively, between the phenyl ring 
planes in the 2-, 4- and 5-positions of the imidazole ring. The molecules are packed in layers 
running perpendicular to the b axis.  There are acceptor and donor atoms for hydrogen bonds. 
The synthesis of novel 2,4,5-triphenylimidazole derivatives seems to be main focus of 
the medicinal research  because compounds containing triphenyl imidazole moiety provides a 
number of needful biological activities such as  analgesic and antiinflammatory activities 
(Shallini et al., 2011; Achar  et al., 2010). Antiinflammatory activity (Yasodha et al., 2009). 
The substitution at C-2 benzene nucleus with benzyl, benzoyl, para amino benzoyl  antifungal 
activity (Yadav et al., 2011). The 2,4,5-triphenyl nucleus had been synthesized by microwave 
technique as well (Pandit et al., 2011). The trimethoxy benzene nucleus at the 2 position of 
imidazole ring in antiinflammatory and antifungal activities (Umarani et al., 2011). Addition 
of thiol group in 2,4,5-triphenylimidazole in increased activity (El Ashry et al., 2007). 
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 Azole ring in place of abstractable hydrogen in 2,4,5-triphenylimidazole ring  potent 
antibacterial and antiinflammatory activity (Amir et al., 2011). 
On the basis of various literature surveys Imidazole derivatives shows various 
pharmacologicalactivities 
 Anti fungal and Anti-bacterial activity 
 Anti inflammatory activity and analgesic activity 
 Anti tubercular activity 
 Anti depressant activity 
 Anti cancer activity 
 Anti viral activity 
 Antileishmanial activity 
 Anti arthritic activity 
 Anti angiogenesis 
In this present study  1-H substituted 2,4,5 triphenyl imidazole derivative  are 
designed, synthesized and their biological activities were screened. 
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METHODS OF TRIPHENYL IMIDAZOLE PREPARATION 
1) CONVENTIONAL HEATING: BURUNGALE SWATI et al., (2013) 
O
O
+ 2NH3
100
0
C reflex for 5 - 24 hrs
N
H
N
1,2-diphenylethane-1,2-dione
2,4,5-triphenyl-1H-imidazole
ammonia
 
2) CATALYST USED : NANA V.SHITOLE et al., (2009)
O
O
+
O
+ NH4OAc
N  Pyroline
Ethanol, Reflux
N
H
N
1,2-diphenylethane-1,2-dione
benzaldehyde 2,4,5-triphenyl-1H-imidazole
 
3) RADISZEWSKI SYNTHESIS:
 
O
O
+
O
NH3
N
H
N
1,2-diphenylethane-1,2-dione
benzaldehyde
2,4,5-triphenyl-1H-imidazole
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MOLECULAR DESIGN 
Molecular design is the process of finding new medicines based on the knowledge of 
a biological target, it enabled the chemist to predict the structure and the value of certain 
properties of various compounds. 
It also allows the medicinal chemist to evaluate the interaction between a compound 
and its target site before synthesizing a compound so as to increase the ability by reducing the 
side effects. 
VARIOUS SOFTWARE USED IN MOLECULAR DESIGN: 
 CHESKETCH 
 CHEMDOODLE 
 MOLINSPIRATION 
 LIPINSKI`S RULE: 
 Molecular weight should be less than 500. 
 Log p value should be less than 5. 
 Number of H-bond donors should be less than 5. 
 Number of H- bond acceptor should be less than 5. 
 Molar refractivity should be less than 150. 
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SPECTROSCOPY(45,46,48,49) 
Study of interaction of electromagnetic radiation with various matters. 
METHOD PRINCIPLE AND APPLICATION  MOLECULAR 
PHENOMENON 
INFRARED 
SPECTROSCOPY  
Structure determination and identity 
of organic and inorganic compounds, 
generally quantitative analysis. 
Excitation of molecular 
vibrations by light 
absorption. 
HNMR 
SPECTROSCOPY  
Structure determination and identity 
organic compounds, molecular 
conformation. 
Re-orientation of magnetic 
nuclei in a magnetic field.  
MASS  
SPECTROSCOPY 
Structure determination and identity 
of organic compounds, analysis of 
trace volatiles in non volatiles. 
Ionization of molecules and 
cracking of molecules into 
fragment ion. 
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ANTIBACTERIAL ACTIVITY(21,25,42,51-53) 
Antibacterial agents: 
The drug which inhibits or destroys the growth of bacteria 
ORGANISM USED FOR ACTIVITY: 
 Bacillus subtilis: 
 Gram positive bacteria. 
 Rod shaped 
 Responsible for food- borne illness. 
Klebsiella pneumonia: 
 Gram negative bactria. 
 Non motile 
 Infection of surgical wounds &respiratory tract 
Mechanism: 
Antibacterial agents inhibit 
 Cell wall synthesis 
 Protein synthesis 
 Nucleic acid synthesis 
 Enzymatic activity 
 Folate metabolism 
Evaluation methods: 
 Turbidimetric method 
 Agar cup plate method 
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ANTIFUNGAL ACTIVITY(21,25,42,51-53) 
Antifungal agents: 
The drugs which are inhibit or destroy the growth of fungus. 
Candida albicans: 
  It causes cutaneous candidiasis 
  Infections found in genitals 
  Spread by direct or sexual contact 
 Prevented by means of hygiene 
Aspergillusniger:  
 It causes Aspergillosis 
 It causes black molds on fruits and vegetables 
 Common symptom is fungal ear infection 
Mechanism: 
 Cell membrane disruption 
 Inhibition of cell division  
 Inhibition of cell wall formation 
 
Evaluation methods: 
 Turbidimetric method 
 Agar cup-plate method 
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ANTI-OXIDANT (54,56,57) 
Antioxidants are chemicals that block the activity of other chemicals known as free 
radicals. 
Antioxidants are chemicals that interact with and neutralize free radicals thus 
preventing them from causing damage. Antioxidant is also known as free radical scavengers. 
Antioxidants are compounds in foods that neutralize chemicals ( free radical) 
produced by oxidation in the human body. These have been linked to disease such as heart 
and liver disease and cancer. 
The process of oxidation in the human body damage cell membranes and others 
structures including cellular proteins lipids and DNA.  When oxygen is metabolized it creates 
unstable molecules called free radicals. 
The effect of free radicals: 
 Deterioration of the eye lens which contributes to blindness 
 Inflammation of the joints 
 Damage to nerve cells in the brain 
 Acceleration of the ageing process 
 Increased risk of coronary heart disease since free radicals encourage low 
density. 
 Lipoprotein(LDL) cholesterol to stick to artery walls 
 Certain cancers triggered by damage cell DNA. 
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Source of antioxidant: 
 Fruits 
 Vegetables                                                                                                                 
 Meats 
 Poultry 
 Fish 
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ANTI-ARTHRITIS (27,38,40,56) 
Definition: 
It is a form of joint disorder that involves inflammation of one or more joints. 
Type of arthritis:    
There are over 100 different form of arthritis.  
The most common from  
 Autoimmune disease: 
 Rheumatoid arthritis 
  Psoriatic arthritis  
 Osteoarthrititis 
 
 Autoimmune disease: 
Rheumatoid arthritis: 
Is an autoimmune disease in which there is joint inflammation, synovial proliferation 
and destruction of articular cartilage. Immune complexes composed of Igm activate 
complement and release cytokines which are chemotactic for neutrophils. These 
inflammatory cells secrete lysosomal enzymes which damagecartilage and erode bone, while 
PGS produced in the process cause vasodialation and pain. 
Psoriasis : 
Develop into psoriatic arthritis. With psoriatic arthritis, most individuals develop the 
skin problem first and then the arthritis. The typical features are of continuous joint pains, 
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stiffness and swelling. The disease does recur with periods of remission but there is no cure 
for than disorder. 
Osteoarthritis: 
Is an degenerative joint disease.  In the aged and children, pain might not be the main 
presenting feature; the aged patient simply moves less, the infantile patient refuses to use the 
affected limb. 
 Causes: 
 Joint pain  
 Inflammation 
 Muscle strain 
 Weight loss 
 Poor sleep 
 Tenderness 
 Symptoms: 
 Joint pain tenderness and stiffness 
 Inflammation and around the joints 
 Restricted movement of the joint 
 Warmth and redness of the skin 
 Weakness and muscle wasting 
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ANTI – ANGIOGENESIS(55-58) 
Definition: 
Angiogenesis is the process of making new blood vessels. 
The term comes from two Greek words, angio meaning blood vessel, and genesis 
meaning beginning. 
Angiogenesis is first named by Herting in 1935, mechanism revealed by Folkman. 
When potential anti- angiogenesis drug were first tested in the lab in the late 1990s 
Anti- angiogenesis is a form of targeted therapy that uses drugs or other substances to 
stop tumors from making new blood vessels. Without a blood supply tumors can’t grow. 
One promising cancer treatment to come from this research is called anti-
angiogenesis. 
Hope of Angiogenesis: 
 Drugs might replace chemotherapy 
 Offering a more effective 
 Less toxic way to treat cancer 
Types of anti angiogenesis treatment: 
1) Drugs that block blood vessel growth factor 
Some drugs block vascular endothelial growth factor (VEGF) from attaching to the receptors 
on the cells that line blood vessels.  This stops the blood vessels from growing. 
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2) Drugs that block signaling within the cell                                             
Some drugs stop the VEGF receptors from sending growth signals into the 
blood vessel cells. These treatments are also called cancer growth blockers or 
tyrosine kinase inhibitors. 
3) Drugs that effect signals between cells 
Some drugs act on the chemicals that cells use to signal to each other to grow. 
This can block the formation of blood vessels. 
Different type of cancer treatment: 
1) Chemotherapy 
2) Gene therapy 
3) Immune therapy 
4) Oncogenes and tumor suppressor gene 
5) Oral chemo therapy  
   Uses: 
 Wound healing 
 Reproductive function  
 Diabetes retinopathy 
 Arthritis 
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LITERATURE REVIEW 
1) Burungale and bhitre et  al., (2013), 
Synthesis of 2,4,5triphenyl imidazole derivatives and biological evaluation for their 
antibacterial and anti inflammatory activity. 
                                          
N
H
N
O
R             R=       
NH 2
Cl
O
 
2) Sharma et al., (2013), 
Microwave irradiated synthesis of some substituted imidazole derivatives as potential 
antibacterial and anticancer agents. 
                             
N
N
R
R`
R=
N
O
NH 2
R`=
OCH 3
 
3) Burungaleswati et al., (2013),  
Synthesis of 2,4,5triphenyl imidazole derivatives and biological evaluation for their 
analgesic and anti-inflammatory activity. 
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N
H
N
 
4 )Kumar Vikrant et al., (2012), 
A robust and reliable one pot synthetic method has been developed for 2,4,5 tri 
substituted imidazole the synthetic sequence via, a multi – component condensation catalyzed 
by p- toluene sulfonic acid, provides good isolated yields under mild conditions. 
                                   
R
N
H
N
 
                                                                 R=H,CH3,OCH3,Cl 
5)   Rajeev Kharb et al., (2012), 
Synthesis and spectral characterization and anthelmintic evaluation of some novel 
imidazole bearing triazole derivatives. 
 
                                     R2
N
N
N
H
N
NH
HS
R2=C6H5 
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6)  S.M. Ahmed et al., (2012), 
Synthesis and screening of 1H- substituted 2,4,5triphenyl imidazole derivatives. 
 
                                          
A r
-
N
N
A r
-
A r
-
R              R=N,NDiethylamine 
           
7)  RashmiArora et al .,(2012), 
Synthesis of 2,4,5triphenyl imidazole novel mannich bases as potential anti-
inflammatory and analgesic agents. 
                                                   
N
N
CH3  
8)  AK.Rathod et al., (2012), 
Microwave assisted synthesis and characterization of triphenylimidazolyl derivatives 
and their antifungal and anti inflammatory activity. 
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                       OH3C
OH3C
OH3C
N
N
NH
Ar
-
 
                                 Ar=  Diphenylamine 
9)  Adel A. Marzoak et al., (2012), 
Synthesis of 2,4,5triphenyl imidazole derivatives using diethyl ammonium hydrogen 
phosphate as green, fast reusable catalyst. 
N
N
R                        
R=Acidic ionic liquids 
10)  ShaileshP.Zala et al., (2012), 
Synthesis and biological evaluation of 2,4,5triphenyl 1H- imidazole-1-yl 
derivatives.Biological activity of anti inflammatory andante microbial activity. 
N
N
R N H 2 O
R=Methoxy benzene 
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11)  Shahedali et al., (2011),  
Synthesis and characterization of novel series of the imidazoles under solvent free 
conditions by using sodium dihydrogen phosphate. 
                                   
N
N
H
       
12)  Yadav et al., (2011), 
Synthesis, spectral characterization and biological screening of some novel 
synthesized imidazoles. 
                                   
N
N
H
 
 
13)  N.Umarani et al., (2011), 
Exploring  the effects of newer three component aminobenzylated reaction of 
triphenyl imidazole motif as potent antimicrobial and anti-inflammatory agents. 
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                         OH3C
OH3C
OH3C
N
N
NH
Ar
-
 Ar      =       
NHNH
 
 
14)   BhartiAshishet al., (2011),  
Various approaches for synthesis of imidazole derivatives.Inhibition of cytokine 
release. 
                                
N
H
N
N
S
R
F R  =CH3 
15)  Bhatnayar et al., (2011), 
A review of on imidazole their chemistry and pharmacological potentials. 
 
                                   
N
N
H
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16)  Javad safari et al., (2010), 
         A novel and an efficient catalyst for one pot synthesis of 2,4,5 tri substituted 
imidazoles by using microwave irradiation under solvent free conditions. 
                                        
N
N
R  
                                             R  =C6H5 
17)  E.Rajanarendar et al., (2010),  
A mild and efficient four component one pot synthesis of 2,4,5triphenyl –(1H-
imidazolyl) isoxazole catalyzed by cerric ammonium nitrate. 
                                          
N
N
R
 
                                                        R =H,Cl 
18) Yasodha et al., (2009), 
  Synthesis and biological evaluation of some 2,4,5triphenyl imidazole derivative and 
chloro compound of anti-inflammatory and anti microbial activity. 
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N
N R
   R =Cl 
19)  Mohd Amir et al., (2009), 
Design and synthesis of some azole derivatives containing 2,4,5triphenyl imidazole 
moiety as anti inflammatory and antimicrobial agents. 
 
                              
N N
N
SH
N
N
R
  R=   CH3 
20)  Nana V.Shitole et al.,(2009), 
L proline as an efficient catalyst for the synthesis of 2,4,5triaryl -1H- imidazoles. 
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N
N
R R=CH3 
21)  Deana Wahyuningrum et al., (2008), 
The correlation between structure and corrosion inhibition activity of 4,5 Diphenyl -1-
vinyl imidazole derivative compounds towards mild steel in 1% sodium chloride solution. 
                               
N
H
N
R
R  = C6H5 
22 )Arshiaparveen et al.,( 2007) 
 Efficient synthesis of 2,4,5triaryl substituted imidazoles under solvent free 
conditions at room temperature.  
                           
N
H
N
R
        R=H 
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23)  Yusuf  ozkay et al., 
Synthesis and biological evaluation of 2,4,5triphenyl imidazole derivative. 
                         
N
H
N
+
CH3
N
O
CH3
S
R
R  =CH3 
24) A series of N-((2-substituted phenyl)-4,5-diphenyl-1H-imidazol-1yl)(phenyl)methyl) 
substituted amine derivatives have been synthesized by 2-substituted 4,5-diphenyl imidazole 
derivatives starting from benzyl and aromatic aldehyde. The newly synthesized compounds 
were screened for analgesic and anti-inflammatory activities. 
                             
N
N
NH
Cl
Cl  
25) A series of 2, 4,5 triphenyl-1H-imidazole-1-yl derivatives have been synthesized and 
tested for their antiinflammatory activity in vitro using Phenylbutazone as a reference drug 
and antimicrobial activity using clotrimazole and ciprofloxacin as a standard drug. All the 
synthesized compounds were screened for their anti-fungal activity against Candida 
albicansand for antimicrobial activity against B. subtilisand E. coli. Compound 8 was found 
to be the most potent derivative of the series. 
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N
N
O
NH
CH3
 
26)  Radiszewski    reported the condensation of a dicarbonyl compound, benzil, and keto 
aldehyde, benzaldehyde, or diketones in the presence of ammonia yield 2,4,5triphenyl 
imidazole. 
                                        
N
N
O
R  
27) A new aryl imidazoles incorporated with chemotherapeutic pharmacophores have been 
synthesized and evaluated for their anti bacterial and short term anti cancer activity. All the 
synthesized substituted imidazoles have shown good antibacterial activity against gram 
negative bacterial strains Klebsiellapneumoniae and Escherichia Coli. 
                                 
N
N
N
CH3
CH3
NH N
H  
 
 
 
Chapter II                                                                            Literature Review 
 
Department of Pharmaceutical Chemistry, MMC, Madurai. Page 26 
 
28)Safari et al., 
Ammonium Molibidate was used as an efficient catalyst for an improved and rapid 
synthesis of 2,4,5 trisubstituted imidazoles by a three component, one pot condensation of 
benzyl, aryl aldehyde, ammonium acetate in good yield under solvent free condition using 
microwave irradidation. 
                            
N
N
R  
29)  Satyajit et al., 
A series of 2- substituted 4,5diphenyl imidazole were synthesized by refluxing bezil 
with differrent substituted aldehydes in the presence of ammonium acetate and glacial acetic 
acid.  Compounds were screened for anthelmintic activity. 
                               
N
H
N
 
30)  Marzoukadel et al., 
Synthesisof 2,4,5triphenyl imidazole derivative using diethyl ammonium hydrogen 
phosphate as green fast and reusable catalyst. 
                               
N
H
N
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AIM AND OBJECTIVE 
AIM OF PRESENT STUDY: 
Triphenylimdazole is a best nucleus and biologically active molecule. Now a day this 
is interesting research nucleus of substituted derivative.  
The aim of the present study was to obtain triphenyl imidazole as biologically 
effective agent with good therapeutic values and minimum toxic levels. 
Past few years most of the research fellowship has done the project in 
triphenylimidazole by the substitution of primary amine in the position of 1H group in 
imidazole. But I like to alter the simple modification in the synthesis for evaluate the anti -
arthritic anti – oxidant, anti angiogenesis and anti microbial activities. 
Step 1 
Here I decided to substitute the different aldehyde in the reaction of benzil and ammonium 
acetate. 
Step 2 
Here I decided to substitute the different amine in the reaction of triphenyl imidazole and 
formaldehyde. 
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OBJECTIVE OF PRESENT WORK: 
 Synthesis: 
Step  I: 
 Synthesis of tri phenyl imidazole derivative. 
Step II: 
 Synthesis of 2,4,5triphenyl -1H-imidazole derivatives 
(compound A1- A5). 
 Synthesis of 5-(chlorophenyl)-2,4diphenyl -1H-imidazole 
derivatives (compound  A6 –A1). 
 Software used: 
 Chemskech 
 Chemdoodle 
 Molinspiration 
 Spectral studies: 
 Infrared spectroscopy 
 Nuclear Magnetic Resonance spectroscopy 
 Mass spectroscopy 
 Biological evaluation: 
 In vitro Antimicrobial Activity 
 In vitro Antioxidant Activity 
 In vitro Antiarthritic Activity 
 In vivo Antiangiogenesis Activity. 
 
                                  
 
   
 SCHEME OF    
                  REACTION 
                  
 
 
 
 
 
 
 
Chapter IV                                                                          Scheme of Reaction 
 
Department of Pharmaceutical Chemistry, MMC, Madurai. Page 29 
SCHEME OF REACTION 
STEP –I PREPARATION OF2,4,5 TRIPHENYL -1H-IMIDAZOLE 
COMPOUND  A 
O
O
1,2-diphenylethane-1,2-dione
+
OHC
benzaldehyde
AMMONIUM ACETATE
GLACIAL ACETIC ACID N
H
N
2,4,5-triphenyl-1H-imidazole
 
STEP –I PRREPARATION OF  5-(4CHLOROPHENYL)2,4DIPHENYL- 1H-
IMIDAZOLE 
COMPOUND   B 
O
O
+
CHO
Cl
AMMONIUM ACETATE
GLACIAL ACETIC ACID
BENZIL
N
H
N
Cl
4-chlorobenzaldehyde 5-(4-chlorophenyl)-2,4-diphenyl-1H-imidazole
 
 
 
Chapter IV                                                                          Scheme of Reaction 
 
Department of Pharmaceutical Chemistry, MMC, Madurai. Page 30 
STEP –II  
PREPARATION OF 1H- SUBSTITUTED TRIPHENYL 
IMIDAZOLE DERIVATIVES 
 COMPOUND   A1  -   A5(A - DERIVATIVE)
N
N
H
+ HCHO + R NH
N
N
R
2,4,5-triphenyl-1H-imidazole
Formaldehyde
Ethanol
COMPOUND A1  -  A5
secondary amine
 
          COMPOUND                        R                     
 A1  Pyrrole 
 A2  Piperzine 
 A3  Diphenyl amine 
 A4  Pyrrolidine 
 A5  Dimethyl amine 
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STEP – II 
PREPARATION OF SUBSTITUTED 5-(4-CHLOROPHENYL)-2,4-DIPHENYL- 
1H- IMIDAZOLE DERIVATIVES 
COMPOUND  A6 – A10 (B - DERIVATIVE) 
                  
N
N
HCl
+ +
Ethanol
N
N
Cl R
R NHHCHO
Formaldehyde
COMPOUND A6  -  A10
5-(4-chlorophenyl)-2,4-diphenyl-1H-imidazole
Secondary amine
 
       COMPOUND                    R                         
 A6  Pyrrole 
 A7  Piperzine 
 A8  Diphenyl amine 
 A9  Pyrrolidine 
 A10  Dimethyl amine 
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EXPERIMENTAL PROCEDURE(5,33) 
COMPOUND  - A 
STEP  - I 
PREPARATION OF 2,4,5 TRIPHENYL -1H- IMIDAZOLE 
 
CHEMICAL REQURIEDS: 
Benzil    - 1gm 
Ammonium acetate - 1gm 
Benzaldehyde    - 2ml 
Glacial acetic acid   - 2ml 
 
PROCEDURE: 
Benzil (1gm),Ammonium acetate (1gm), Benzaldehyde(2ml),Glacial acetic acid(2ml) are 
reflux for 3hours.the reaction mixture was allowed to stand to attain room temperature. To that 
add 150 ml of water, the solid thus obtained was filtered. The filterate is neutralized with 
ammonium hydroxide or sodium carbonate to give solid pasty mass and filtered. Then the solid 
mass was washed with toluene and recrystalized from methanol.  
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STEP - 1 
COMPOUND  - A 
  PREPARATION OF 2,4,5 TRIPHENYL -1H- IMIDAZOLE 
 
             
O
O
1,2-diphenylethane-1,2-dione
+
OHC
benzaldehyde
AMMONIUM ACETATE GLACIAL ACETIC ACID
N
H
N
2,4,5-triphenyl-1H-imidazole  
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STEP -  I 
COMPOUND -B 
 PREPARATION OF  5-(4-CHLOROPHENYL)-2,4-DIPHENYL- 1H- IMIDAZOLE 
 
CHEMICAL REQUIREDS: 
Benzil     - 1gm 
Ammonium acetate   - 1gm 
P-ChloroBenzaldehyde  - 2ml 
Glacial acetic acid        - 2ml 
 
PROCEDURE: 
Benzyl (1gm),Ammonium acetate (1gm)P-ChloroBenzaldehyde(2ml),Glacial acetic 
acid(2ml) are reflux for 3hours.the reaction mixture was allowed to stand to attain room 
temperature. To that add 150 ml of water, the solid thus obtained was filtered. The filterate is 
neutralized with ammonium hydroxide or sodium carbonate to give solid pasty mass and filtered. 
Then the solid mass was washed with toluene and recrystalized from methanol.  
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STEP -  I 
  COMPOUND -B 
PREPARATION OF  5-(4-CHLOROPHENYL)-2,4- 
DIPHENYL- 1H- IMIDAZOLE 
                               
O
O
+
CHO
Cl
AMMONIUM ACETATE GLACIAL ACETIC ACID
BENZIL
N
H
N
Cl
4-chlorobenzaldehyde
5-(4-chlorophenyl)-2,4-diphenyl-1H-imidazole  
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STEP  -II(COMPOUND A DERIVATIVE) 
COMPOUND A1 
Synthesis of 2,4,5triphenyl -1-(1H-pyrrol-1-yl) -1H- imidazole 
CHEMICAL REQUIREDS: 
Triphenyl imidazole   -  0.01M 
Formaldehyde   - 3gm 
Ethanol in pyrrole   - 10% 
PROCEDURE: 
The mixture of ethanolic solution of 0.01M compound and formaldehyde 3gm was added 
slowly to ethanolic solution of pyrrole  the reaction mixture is stirred more than one hour at room 
temperature and kept it over night in a refrigerator the solid form is filtered and is washed with 
ethanol. 
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N
H
N
2,4,5-triphenyl-1H-imidazole
+ HCHO
Formaldehyde
+
Ethanol
N
N
N
2,4,5-triphenyl-1-(1H-pyrrol-1-yl)-1H-imidazole
COMPOUND  A1
Molecular Formula  = C25H19N3
Formula Weight  = 361.43846
Composition  =  C(83.08%) H(5.30%) N(11.63%)
Molar Refractivity  = 115.98 ± 0.5 cm3
Molar Volume  = 318.5 ± 7.0 cm3
Parachor  = 833.6 ± 8.0 cm3
Index of Refraction  = 1.648 ± 0.05
Surface Tension  = 46.8 ± 7.0 dyne/cm
Density  = 1.13 ± 0.1 g/cm3
Dielectric Constant  = Not available
Polarizability  = 45.98 ± 0.5 10-24cm3
Monoisotopic Mass  = 361.157898 Da
Nominal Mass  = 361 Da
Average Mass  = 361.4385 Da
N
H
1H-pyrrole
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COMPOUND A2 
Synthesis of 2,4,5triphenyl -1-(1H-piperzine-1-yl) -1H- imidazole 
CHEMICAL REQUIREDS: 
Triphenyl imidazole  -  0.01M 
Formaldehyde  - 3gm 
Ethanol in Piperzine  - 10% 
PROCEDURE: 
The mixture of ethanolic solution of 0.01M compound and formaldehyde 3gm was added 
slowly to ethanolic solution of piperzine  the reaction mixture is stirred more than one hour at 
room temperature and kept it over night in a refrigerator the solid form is filtered and is washed 
with ethanol. 
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N
H
N +
HCHO +
N
H
N
H
Ethanol
N
N
N
N
H
2,4,5 triphenyl - 1 -  (1H piperzine - 1 -  yl) - 1H -  imidazole
2,4,5-triphenyl-1H-imidazole
piperazine
Formaldehyde
COMPOUND  A2
Molecular Formula  = C25H24N4
Formula Weight  = 380.48486
Composition  =  C(78.92%) H(6.36%) N(14.73%)
Molar Refractivity  = 119.03 ± 0.5 cm3
Molar Volume  = 323.2 ± 7.0 cm3
Parachor  = 853.3 ± 8.0 cm3
Index of Refraction  = 1.657 ± 0.05
Surface Tension  = 48.5 ± 7.0 dyne/cm
Density  = 1.17 ± 0.1 g/cm3
Dielectric Constant  = Not available
Polarizability  = 47.19 ± 0.5 10-24cm3
Monoisotopic Mass  = 380.200097 Da
Nominal Mass  = 380 Da
Average Mass  = 380.4849 Da  
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COMPOUND A3 
Synthesis of  N,N diphenyl-2,4,5 triphenyl -1H- Imidazole- 1- amine 
CHEMICALS REQUIRED: 
Triphenyl imidazole  -  0.01M 
Formaldehyde   - 3gm 
 Ethanol in Diphenyl amine   - 10% 
PROCEDURE: 
The mixture of ethanolic solution of 0.01M compound and formaldehyde 3gm was added 
slowly to ethanolic solution of diphenyl amine  the reaction mixture is stirred more than one hour 
at room temperature and kept it over night in a refrigerator the solid form is filtered and is 
washed with ethanol. 
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N
N
H
2,4,5-triphenyl-1H-imidazole
+ HCHO +
Ethanol
H5C6
NH
H5C6
N-phenylaniline
Formaldehyde
N
N
N
H5C6 C6H5
N,N diphenyl - 2,4,5 triphenyl - 1H - imidazol - 1 - amine
COMPOUND  A3
Molecular Formula  = C33H25N3
Formula Weight  = 463.5717
Composition  =  C(85.50%) H(5.44%) N(9.06%)
Molar Refractivity  = 150.30 ± 0.5 cm3
Molar Volume  = 418.4 ± 7.0 cm3
Parachor  = 1087.7 ± 8.0 cm3
Index of Refraction  = 1.637 ± 0.05
Surface Tension  = 45.6 ± 7.0 dyne/cm
Density  = 1.10 ± 0.1 g/cm3
Dielectric Constant  = Not available
Polarizability  = 59.58 ± 0.5 10-24cm3
Monoisotopic Mass  = 463.204848 Da
Nominal Mass  = 463 Da
Average Mass  = 463.5717 Da  
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COMPOUND A4 
   Synthesis of 2,4,5triphenyl -1-(1H-pyrrolidin-1-yl) -1H-Imidazole 
CHEMICALS REQUIRRED: 
Triphenyl imidazole   -  0.01M 
Formaldehyde   - 3gm 
Ethanol in pyrrolidine   - 10% 
PROCEDURE: 
The mixture of ethanolic solution of 0.01M compound and formaldehyde 3gm was added 
slowly to ethanolic solution of pyrrolidine  the reaction mixture is stirred more than one hour at 
room temperature and kept it over night in a refrigerator the solid form is filtered and is washed 
with ethanol. 
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N
H
N + HCHO + N
H
Ethanol
N
N
N
2,4,5-triphenyl-1H-imidazole
pyrrolidine
Formaldehyde
2,4,5,triphenyl -1 - (pyrrolidin -1 -yl)-1H - imidazole
COMPOUND   4
Molecular Formula  = C25H23N3
Formula Weight  = 365.47022
Composition  =  C(82.16%) H(6.34%) N(11.50%)
Molar Refractivity  = 115.98 ± 0.5 cm3
Molar Volume  = 318.5 ± 7.0 cm3
Parachor  = 833.6 ± 8.0 cm3
Index of Refraction  = 1.648 ± 0.05
Surface Tension  = 46.8 ± 7.0 dyne/cm
Density  = 1.14 ± 0.1 g/cm3
Dielectric Constant  = Not available
Polarizability  = 45.98 ± 0.5 10-24cm3
Monoisotopic Mass  = 365.189198 Da
Nominal Mass  = 365 Da
Average Mass  = 365.4702 Da  
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COMPOUND A5 
Synthesis of N,N dimethyl 2,4,5 triphenyl-1H- Imidazol - amine 
Triphenyl imidazole   -  0.01M 
Formaldehyde    - 3gm 
Ethanol in dimethyl amine  - 10% 
PROCEDURE: 
The mixture of ethanolic solution of 0.01M compound and formaldehyde 3gm was added 
slowly to ethanolic solution of dimethyl amine the reaction mixture is stirred more than one hour 
at room temperature and kept it over night in a refrigerator the solid form is filtered and is 
washed with ethanol. 
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N
H
N
+
Formaldehyde
+
CH3
CH3
NH
N
N
N
CH3CH3
N,N-dimethyl-2,4,5-triphenyl-1H-imidazol-1-amine
2,4,5-triphenyl-1H-imidazole
N-methylmethanamine
Ethanol
HCHO
COMPOUND    A5
Molecular Formula  = C23H21N3
Formula Weight  = 339.43294
Composition  =  C(81.38%) H(6.24%) N(12.38%)
Molar Refractivity  = 108.94 ± 0.5 cm3
Molar Volume  = 313.2 ± 7.0 cm3
Parachor  = 796.1 ± 8.0 cm3
Index of Refraction  = 1.612 ± 0.05
Surface Tension  = 41.7 ± 7.0 dyne/cm
Density  = 1.08 ± 0.1 g/cm3
Dielectric Constant  = Not available
Polarizability  = 43.18 ± 0.5 10-24cm3
Monoisotopic Mass  = 339.173548 Da
Nominal Mass  = 339 Da
Average Mass  = 339.4329 Da  
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STEP  - II (COMPOUND B DERIVATIVE) 
  COMPOUND A6 
Synthesis of 5-[4- chlorophenyl2,4, diphenyl -1-(1H-pyrrol-1-yl) -1H- imidazole 
CHEMICALS REQURIED: 
5-(4-Chlorophenyl)  -2,4-  
diphenyl- 1H- imidazole -  0.01M 
Formaldehyde   - 3gm 
Ethanol in pyrrole    - 10% 
PROCEDURE: 
The mixture of ethanolic solution of 0.01M compound and formaldehyde 3gm was added 
slowly to ethanolic solution of pyrrole  the reaction mixture is stirred more than one hour at room 
temperature and kept it over night in a refrigerator the solid form is filtered and is washed with 
ethanol. 
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N
N
HCl
5-(4-chlorophenyl)-2,4-diphenyl-1H-imidazole
+ HCHO +
N
H
Ethanol
N
N
Cl
N
5-(4-chlorophenyl)-2,4-diphenyl-1-(1H-pyrrol-1-yl)-1H-imidazole
1H-pyrrole
Formaldehyde
COMPOUND      A6
Molecular Formula  = C25H18ClN3
Formula Weight  = 395.88352
Composition  =  C(75.85%) H(4.58%) Cl(8.96%) N(10.61%)
Molar Refractivity  = 120.58 ± 0.5 cm3
Molar Volume  = 327.8 ± 7.0 cm3
Parachor  = 862.4 ± 8.0 cm3
Index of Refraction  = 1.656 ± 0.05
Surface Tension  = 47.8 ± 7.0 dyne/cm
Density  = 1.20 ± 0.1 g/cm3
Dielectric Constant  = Not available
Polarizability  = 47.80 ± 0.5 10-24cm3
Monoisotopic Mass  = 395.118925 Da
Nominal Mass  = 395 Da
Average Mass  = 395.8835 Da  
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COMPOUND A7 
Synthesis of 5-(4-chlorophenyl)2,4, Diphenyl -1H imidazole 1-yl piperzine 
CHEMICALS REQUIRED: 
5-(4-Chlorophenyl)-2,4-  
diphenyl- 1H- imidazole  -  0.01M 
Formaldehyde    - 3gm 
Ethanol in piperzine  - 10% 
PROCEDURE: 
The mixture of ethanolic solution of 0.01M compound and formaldehyde 3gm was added 
slowly to ethanolic solution of piperzine the reaction mixture is stirred more than one hour at 
room temperature and kept it over night in a refrigerator the solid form is filtered and is washed 
with ethanol. 
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N
N
HCl
+
Formaldehyde
HCHO +
N
H
N
H
Ethanol
N
N
Cl
N
N
H
5-(4-chlorophenyl)-2,4-diphenyl-1H-imidazole
piperazine
COMPOUND  A7
Molecular Formula  = C25H23ClN4
Formula Weight  = 414.92992
Composition  =  C(72.37%) H(5.59%) Cl(8.54%) N(13.50%)
Molar Refractivity  = 123.64 ± 0.5 cm3
Molar Volume  = 332.5 ± 7.0 cm3
Parachor  = 882.2 ± 8.0 cm3
Index of Refraction  = 1.666 ± 0.05
Surface Tension  = 49.5 ± 7.0 dyne/cm
Density  = 1.24 ± 0.1 g/cm3
Dielectric Constant  = Not available
Polarizability  = 49.01 ± 0.5 10-24cm3
Monoisotopic Mass  = 414.161124 Da
Nominal Mass  = 414 Da
Average Mass  = 414.9299 Da
5-(4-chlorophenyl)-2,4-diphenyl -1Himidazole -1-yl piperzine
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COMPOUND A8 
Synthesis of 5- (4-Chlorophenyl) N,N diphenyl-1H-imidazol amine 
CHEMICALS REQUIRED: 
5-(4-Chlorophenyl)-2,4-  
                        diphenyl- 1H- imidazole  -  0.01M 
Formaldehyde   - 3gm 
Ethanol in diphenyl amine  - 10% 
PROCEDURE: 
 The mixture of ethanolic solution of 0.01M compound and formaldehyde 3gm was 
added slowly to ethanolic solution of diphenyl amine the reaction mixture is stirred more than 
one hour at room temperature and kept it over night in a refrigerator the solid form is filtered and 
is washed with ethanol. 
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N
N
HCl
+
Formaldehyde
HCHO +
H5C6
NH
H5C6
Ethanol
N
N
H5C6
N
C6H5
Cl
5-(4-chlorophenyl)-2,4-diphenyl-1H-imidazole
N-phenylaniline
5 -(4 -chlorophenyl)N,N diphenyl 2,4 diphenyl  - 1H - imidazol amine
COMPOUND  A8
Molecular Formula  = C33H24ClN3
Formula Weight  = 498.01676
Composition  =  C(79.59%) H(4.86%) Cl(7.12%) N(8.44%)
Molar Refractivity  = 154.90 ± 0.5 cm3
Molar Volume  = 427.6 ± 7.0 cm3
Parachor  = 1116.5 ± 8.0 cm3
Index of Refraction  = 1.644 ± 0.05
Surface Tension  = 46.4 ± 7.0 dyne/cm
Density  = 1.16 ± 0.1 g/cm3
Dielectric Constant  = Not available
Polarizability  = 61.41 ± 0.5 10-24cm3
Monoisotopic Mass  = 497.165875 Da
Nominal Mass  = 497 Da
Average Mass  = 498.0168  
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COMPOUND A9 
Synthesis of 5-(4-chlorophenyl) 2,4diphenyl -1-(pyrrolidin -  1-yl)-1H- imidazole 
CHEMICALS REQUIRED: 
5-(4-Chlorophenyl)-2,4-  
diphenyl- 1H- imidazole  -  0.01M                                                                                                    
Formaldehyde   - 3gm 
Ethanol in pyrrolidine  - 10% 
PROCEDURE: 
The mixture of ethanolic solution of 0.01M compound and formaldehyde 3gm was added 
slowly to ethanolic solution of pyrrolidine  the reaction mixture is stirred more than one hour at 
room temperature and kept it over night in a refrigerator the solid form is filtered and is washed 
with ethanol. 
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N
H
N
Cl
+ HCHO +
N
H
Ethanol
Formaldehyde
5-(4-chlorophenyl)-2,4-diphenyl-1H-imidazole
pyrrolidine
N
N
Cl
N
5 -(4 -chlorophenyl) 2,4 diphenyl -1 -(pyrrolidin - 1 - yl) - 1H - imidazole
COMPOUND  A9
Molecular Formula  = C25H22ClN3
Formula Weight  = 399.91528
Composition  =  C(75.08%) H(5.54%) Cl(8.87%) N(10.51%)
Molar Refractivity  = 120.58 ± 0.5 cm3
Molar Volume  = 327.8 ± 7.0 cm3
Parachor  = 862.4 ± 8.0 cm3
Index of Refraction  = 1.656 ± 0.05
Surface Tension  = 47.8 ± 7.0 dyne/cm
Density  = 1.21 ± 0.1 g/cm3
Dielectric Constant  = Not available
Polarizability  = 47.80 ± 0.5 10-24cm3
Monoisotopic Mass  = 399.150225 Da
Nominal Mass  = 399 Da
Average Mass  = 399.9153 Da  
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COMPOUND A10 
Synthesis of 5-(4-chlorophenyl)- N,N-dimethyl 2,4 diphenyl- 1H-imidazol-1-amine 
CHEMICALS REQUIRED: 
5-(4-Chlorophenyl)-2,4-  
diphenyl- 1H- imidazole   -  0.01M 
Formaldehyde   - 3gm 
Ethanol in dimethyl amin  - 10%            
PROCEDURE: 
The mixture of ethanolic solution of 0.01M compound and formaldehyde 3gm was added 
slowly to ethanolic solution of dimethyl amine the reaction mixture is stirred more than one hour 
at room temperature and kept it over night in a refrigerator the solid form is filtered and is 
washed with ethanol. 
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N
N
HCl
+
Formaldehyde
HCHO +
CH3
CH3
NH
N
N
Cl
CH3
N
CH3
5-(4-chlorophenyl)-N,N-dimethyl-2,4-diphenyl-1H-imidazol-1-amine
5-(4-chlorophenyl)-2,4-diphenyl-1H-imidazole
N-methylmethanamine
Ethanol
COMPOUND   A10
Molecular Formula  = C23H20ClN3
Formula Weight  = 373.878
Composition  =  C(73.89%) H(5.39%) Cl(9.48%) N(11.24%)
Molar Refractivity  = 113.54 ± 0.5 cm3
Molar Volume  = 322.5 ± 7.0 cm3
Parachor  = 825.0 ± 8.0 cm3
Index of Refraction  = 1.621 ± 0.05
Surface Tension  = 42.8 ± 7.0 dyne/cm
Density  = 1.15 ± 0.1 g/cm3
Dielectric Constant  = Not available
Polarizability  = 45.01 ± 0.5 10-24cm3
Monoisotopic Mass  = 373.134575 Da
Nominal Mass  = 373 Da
Average Mass  = 373.878 Da  
                                                     
MOLECULAR DESGIN 
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MOLECULAR DESIGN 
CHEMDOODLE 
COMPOUND   A1 
 2,4,5triphenyl -1-(1H-pyrrol-1-yl) -1H- imidazole 
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COMPOUND   A2 
 2,4,5triphenyl -1-(1H-piperzine-1-yl) -1H- imidazole 
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 COMPOUND   A3 
 N,N diphenyl-2,4,5 triphenyl -1H- Imidazole- 1- amine 
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COMPOUND    A4 
  2,4,5triphenyl -1-(1H-pyrrolidin-1-yl) -1H-Imidazole 
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COMPOUND   A5 
N,N dimethyl 2,4,5 triphenyl-1H- Imidazol - amine 
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C0MPOUND    A6 
 5-[4- chlorophenyl2,4, diphenyl -1-(1H-pyrrol-1-yl) -1H- imidazole 
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COMPOUND   A7 
 5-(4-chlorophenyl)2,4, Diphenyl -1H imidazole 1-yl piperzine 
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COMPOUND   A8 
 5- (4-Chlorophenyl) N,N diphenyl-1H-imidazol amine 
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COMPOUND    A9 
 5-(4-chlorophenyl) 2,4diphenyl -1-(pyrrolidin -  1-yl)-1H- imidazole 
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COMPOUND   A10 
 5-(4-chlorophenyl)- N,N-dimethyl 2,4 diphenyl- 1H-imidazol-1-amine 
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LIPINSKIS RULE BY CHEMDOODLE 
Table.No:1 
Code    M.W M.R 
cm3/mol 
     H bond    
    acceptor     
      H bond 
       donor 
   Log   P No.of.criteria 
Rule <500 <150 <10 <5 <5 Atleast   3 
 
A1   361.4      113.8         0        0      6.2        4 
 
A2   380.4      119.3          2        1       5.8        4 
 
A3   463.5      150.3           1        0       8.1        4 
 
A4   365.4      115.7          1        0       6.2        4 
 
A5   339.4      108.6          1        0        5        4 
 
A6   395.8      118.7          0        0        6.8        4 
 
A7   414.9      123.4           2        1        6.4        4 
 
A8   498      153.9          1        0        8.7        4 
 
A9   399.9         120          1        0        6.9        4 
 
A10   373.8      113.6          1         0        5.6        4 
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MOLINSPIRATION 
Calculation of molecular properties and bioactivity score 
COMPOUND  A1 
 
 
 
 
 
Molinspiration property engine v2013.09
miLogP         6.038 
TPSA           22.76 
natoms         28.0 
MW             361.448 
nON            3 
nOHNH          0 
nviolations    1 
nrotb          4 
volume         336.256 
 
Molinspiration bioactivity score v2011.06 
GPCR ligand                -0.12 
Ion channel modulator      -0.13 
Kinase inhibitor            0.03 
Nuclear receptor ligand    -0.22 
Protease inhibitor         -0.41 
Enzymeinhibitor           -0.09 
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COMPOUND  A2 
 
 
 
Molinspiration property engine v2013.09 
 
miLogP         4.756 
TPSA           33.091 
natoms         29.0 
MW             380.495 
nON            4 
nOHNH          1 
nviolations    0 
nrotb          4 
volume         361.032 
 
 
 
Molinspiration bioactivity score v2011.06
GPCR ligand                 0.20 
Ion channel modulator      -0.02 
Kinase inhibitor            0.15 
Nuclear receptor ligand    -0.14 
Protease inhibitor         -0.20 
Enzymeinhibitor            0.14 
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COMPOUND A3 
 
 
 
Molinspiration property engine v2013.09
 
miLogP         8.618 
TPSA           21.064 
natoms         36.0 
MW             463.584 
nON            3 
nOHNH          0 
nviolations    1 
nrotb          6 
volume         435.081 
 
Molinspiration bioactivity score v2011.06 
GPCR ligand                -0.02 
Ion channel modulator      -0.09 
Kinase inhibitor            0.10 
Nuclear receptor ligand    -0.07 
Protease inhibitor         -0.24 
Enzymeinhibitor           -0.00 
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COMPOUND A4 
 
 
 
Molinspiration property engine v2013.09
 
miLogP         5.863 
TPSA           21.064 
natoms         28.0 
MW             365.48 
nON            3 
nOHNH          0 
nviolations    1 
nrotb          4 
volume         348.629 
 
Molinspiration bioactivity score v2011.06 
GPCR ligand                 0.08 
Ion channel modulator      -0.04 
Kinase inhibitor            0.13 
Nuclear receptor ligand    -0.08 
Protease inhibitor         -0.21 
Enzymeinhibitor            0.10 
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COMPOUND  A5 
 
 
 
 
 
 
Molinspiration property engine v2013.09 
miLogP         5.46 
TPSA           21.064 
natoms         26.0 
MW             339.442 
nON            3 
nOHNH          0 
nviolations    1 
nrotb          4 
volume         325.386 
 
Molinspiration bioactivity score v2011.06 
GPCR ligand                 0.02 
Ion channel modulator      -0.10 
Kinase inhibitor            0.10 
Nuclear receptor ligand    -0.13 
Protease inhibitor         -0.21 
Enzymeinhibitor            0.07 
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 COMPOUND A6 
 
 
Molinspiration property engine v2013.09 
miLogP         6.692 
TPSA           22.76 
natoms         29.0 
MW             395.893 
nON            3 
nOHNH          0 
nviolations    1 
nrotb          4 
volume349.792 
Molinspiration bioactivity scorev2011.06 
GPCR ligand                -0.12 
Ion channel modulator      -0.14 
Kinasssse inhibitor            0.01 
Nuclear receptor ligand    -0.21  
Protease inhibitor         -0.45 
Enzymeinhibitor           -0.11 
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COMPOUND A7 
 
 
 
Molinspiration property engine
v2013.09 
miLogP         5.41 
TPSA           33.091 
natoms         30.0 
MW             414.94 
nON            4 
nOHNH          1 
nviolations    1 
nrotb          4 
volume         374.568 
Molinspiration bioactivity score v2011.06 
GPCR ligand                 0.19 
Ion channel modulator      -0.04 
Kinase inhibitor            0.13 
Nuclear receptor ligand    -0.13 
Protease inhibitor         -0.24 
Enzymeinhibitor            0.11  
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COMPOUND A8 
 
 
 
Molinspiration property engine v2013.09 
 
miLogP         8.92 
TPSA           21.064 
natoms         37.0 
MW             498.029 
nON            3 
nOHNH          0 
nviolations    1 
nrotb          6 
volume         448.617 
Molinspiration bioactivity score v2011.06 
GPCR ligand                -0.02 
Ion channel modulator      -0.13 
Kinase inhibitor            0.09 
Nuclear receptor ligand    -0.07 
Protease inhibitor         -0.28 
Enzymeinhibitor           -0.02S 
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COMPOUND  A9 
 
 
 
Molinspiration property engine v2013.09 
miLogP         6.517 
TPSA           21.064 
natoms         29.0 
MW             399.925 
nON            3 
nOHNH          0 
nviolations    1 
nrotb          4 
volume         362.165 
Molinspiration bioactivity score v2011.06 
GPCR ligand                 0.07 
Ion channel modulator      -0.06 
Kinase inhibitor            0.11 
Nuclear receptor ligand    -0.08 
Protease inhibitor         -0.26 
Enzymeinhibitor            0.07 
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COMPOUND  A10 
 
 
 
Molinspiration property engine v2013.09 
 
miLogP         6.114 
TPSA           21.064 
natoms         27.0       
MW             373.887 
nON            3 
nOHNH          0 
nviolations    1 
nrotb          4 
volume         338.922 
Molinspiration bioactivity score v2011.06 
GPCR ligand                 0.02 
Ion channel modulator      -0.11 
Kinase inhibitor            0.08 
Nuclear receptor ligand    -0.13 
Protease inhibitor         -0.26 
Enzymeinhibitor            0.04 
 
 
       PHYSICAL DATA 
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PHYSICAL DATA OF SYNTHESIZED COMPOUNDS 
 
Table.No:2 
 
CODE MOLECULAR 
FORMULA 
MOLECULAR 
WEIGHT 
 I.U.P.A.C NAME 
A1 C25H19N3 361.438 
 
2,4,5 triphenyl-1-(1H-pyrrole-1-yl)-1H-
imidazole 
A2 C25H24 N4 380.484 
 
2,4,5 triphenyl-1-(1H piperzine-1-yl) -1H- 
imidazole 
A3 C33H25N3 463.57 
 
N,N diphenyl-2,4,5triphenyl -1H-
imidazol-1-amine 
A4 C25H23N3 365.47 
 
2,4,5 Triphenyl-1-(pyrrolidin-1-yl)-1H-
imidazdazole 
A5 C23H21N3 339.43 
 
N,N dimethyl-2,4,5,triphenyl -1H-
imidazol-1-amine 
A6 C25H18ClN3 395.88 
 
5-(4-Chlorophenyl)-2,4-diphenyl-1-(1H-
pyrrole-1-yl)-1H-imidazole 
A7 C25H23ClN4 414.92 
 
5-(4-Chlorophenyl)-2,4-diphenyl-1H 
imidazole-1-yl piperzine 
A8 C33H24ClN3 498.016 
 
5-(4-chlorophenyl)N,N-diphenyl 2,4 
diphenyl-1H-imidazol amine 
A9 C25H22ClN3 399.91 
 
5-(4-chlorophenyl) 2,4 diphenyl-1-
(pyrrolidin-1-yl)-1H-imidazole 
A10 C23H20ClN3 373.87 
 
5-(4-chlorophenyl)-N,N-methyl-
2,4diphenyl-1H-imidazol-1-amine 
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MELTING POINT 
Table.No:3 
COMPOUND APPEARANCE %YIELD MELTING 
POINT -◦C 
SOLUBILITY
 A1 Brown solid    78  130     DMSO 
 A2 Sandal solid    72  110     DMSO 
 A3  White solid    75  125     DMSO 
 A4  White solid    77  140     DMSO 
 A5  Pale white solid    74  120     DMSO 
 A6 Dark brown solid    79  135     DMSO 
 A7  Pale orange solid    70  120     DMSO 
 A8  Pale yellow solid    68  100     DMSO 
 A9 White solid    71  130     DMSO 
 A10  Pale white solid    76  105     DMSO 
 
THIN LAYER CHROMATOGRAPHY(21) 
        The thin layer chromatography was used to determine the purity of the compounds in 
readymade silica gel plate and spots were visualized using iodine chamber.  
SOLVENT SYSTEM USED: 
HEXANE     :     ETHYL ACETATE 
  1               :                1                                                    
Table.No:4 
S.NO COMPOUND Rf 
VALUE 
1  A1      0.64 
2  A2      0.72 
3  A3      0.85 
4  A4      0.61 
5  A5      0.78 
6  A6      0.61 
7  A7      0.75 
8  A8      0.83 
9  A9      0.66 
10  A10      0.80 
 
Chapter VII                                                                                Physical Data  
 
Department of Pharmaceutical Chemistry, MMC, Madurai. Page 79 
 
ELEMENTAL COMPOSITION  ANALYSIS 
     Table.No.5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                          
COMPOUND 
C H N Cl 
 %FOUND 
                   %CALCULATED 
 
A1 
 
 
83.08 
 
5.3 
 
11.63 
 
- 
 
 
A2 
 
 
78.92 
 
6.36 
 
14.73 
 
- 
 
 
A3 
 
 
83.50 
 
5.44 
 
9.06 
 
- 
 
 
A4 
 
 
82.16 
 
6.34 
 
11.5 
 
- 
 
 
A5 
 
 
81.38 
 
6.24 
 
12.38 
 
- 
 
 
A6 
 
 
75.85 
 
4.58 
 
10.6 
 
8.96 
 
 
A7 
 
 
72.37 
 
5.59 
 
13 
 
8.54 
 
 
A8 
 
 
79.59 
 
4.86 
 
8.44 
 
7.12 
 
 
A9 
 
 
75.08 
 
5.54 
 
10.5 
 
8.87 
 
 
A10 
 
 
73.89 
 
5.39 
 
11.24 
 
9.48 
 
  
 
 
 
               SPECTRAL DATA 
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MATERIALS AND METHODS(45,46,48,49) 
  INFRARED SPECTROSCOPY: 
 IR is concerned with study of absorption of infrared radiation, which 
results in vibrational transition. 
 Instrument – Shimadzhu FTIR 
 Region 4000  -   400cm-1 
 Method -      pressed pellet technique  
 Values measured in cm¯1 
1HNMR SPECTROSCOPY:  
 NMR is the study of spin changes at the nuclear level when radio 
frequency energy is absorbed in the presence of magnetic field. 
 Instrument  - BrukerAvance II 400 NMR 
 Solvent used  -DMSO 
 Tetra Methyl Silane used as internal standard  
 Values measured in delta ppm 
MASS SPECTROSCOPY: 
 It can be used to determine directly molecular weight 
 The compound under investigation is bombared with a beam of 
electrons which produce an ionic molecule (or) ionic fragments 
of the original species 
 The molecular ion is called as parent ion and it is designed as M+. 
 The largest peak in the structure is called base peak. 
 The molecular ion peak should have the largest m/e ratio. 
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INFRARED SPECTROSCOPY 
COMPOUND  A1 
 
COMPOUND  A2 
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COMPOUND  A3 
 
COMPOUND   A4 
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COMPOUND   A5 
 
COMPOUND   A6 
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COMPOUND   A7 
 
       COMPOUND   A8 
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COMPOUND   A9 
 
 
COMPOUND  A10 
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INFRARED SPECTROSCOPY DATAS 
Table.No:6 
 
 
                             
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CODE 
TYPES OF 
VIBRATION 
OBSERVED 
VALUE (cm-1) 
A1 
C=C str,in benzene 
CH str aromatic 
C – C  str 
C – N str 
C = N str 
N – H str 
N – N str 
1598 
2960 
1174 
1325 
1649 
3028 
3444 
A2 
C=C str,in benzene 
CH str aromatic 
C – C  str 
C – N str 
C = N str 
N – H str 
N – N str 
1597 
2939 
1174 
1323 
1658 
3037 
3444 
A3 
C=C str,in benzene 
CH str aromatic 
C – C  str 
C – N str 
C = N str 
N – H str 
N – N str 
1597 
2920 
1197 
1244 
1504 
3010 
3074 
 
A4 
C=C str,in benzene 
CH str aromatic 
C – C  str 
C – N str 
C = N str 
N – H str 
N – N str 
1597 
2941 
1174 
1209 
1658 
3030 
3471 
A5 
C=C str,in benzene 
CH str aromatic 
C – C  str 
C – N str 
C = N str 
N – H str 
N – N str 
1597 
2879 
1174 
1323 
1658 
3037 
3446 
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A6 C=C str,in benzene 
CH str aromatic 
C – C  str 
 C – N str 
 C = N str 
 N – H str 
 N – N str 
 C – Clstr 
         1597 
           2960 
           1174 
            1203 
            1658 
            3132 
            3273 
             767 
A7 C=C str,in benzene 
CH str aromatic 
C – C  str 
 C – N str 
 C = N str 
 N – H str 
 N – N str 
 C – Clstr 
            1597 
            2958 
            1172 
            1346 
            1577 
            3028 
            3444 
              794 
A8 C=C str,in benzene 
CH str aromatic 
C – C  str 
 C – N str 
 C = N str 
 N – H str 
 N – N str 
 C – Clstr 
             1591 
            2962 
            1174 
            1325 
            1668 
            3026 
            3059 
              767      
A9 C=C str,in benzene 
CH str aromatic 
C – C  str 
 C – N str 
 C = N str 
 N – H str 
 N – N str 
 C – Clstr 
            1598         
            2960 
            1174 
            1325 
            1658 
            3026 
            3446 
              767      
A10 C=C str,in benzene 
CH str aromatic 
C – C  str 
 C – N str 
 C = N str 
 N – H str 
 N – N str 
 C – Clstr 
            1597 
          2960 
          1174 
          1211 
          1674 
          3026 
          3444 
           767  
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1HNMR SPECTROSCOPY 
 
COMPOUND  A1           Current Data Parameters
               NAME  Feb08−2014
               EXPNO  11
        PROCNO 1
               F2 − Acquisition Parameters
               Date_  20140208
               Time  22.10
               INSTRUM spect
               PROBHD 5 mm PABBO BB−
               PULPROG zg30
               TD  32768
               SOLVENT DMSO
               NS  32
               DS  2
               SWH  10330.578 Hz
               FIDRES  0.315264 Hz
               AQ  1.5860212 sec
               RG  203
               DW  48.400 usec
               DE  6.50 usec
               TE  300.1 K
               D1 1.00000000 sec
               TD0  1
               ======== CHANNEL f1 ========
               NUC1  1H
               P1  10.65 usec
               PL1  0.00 dB
               PL1W  23.53637505 W
        SFO1 500.1330885 MHz
        F2 − Processing parameters
               SI  32768
               SF 500.1300035 MHz
               WDW  EM
               SSB  0
               LB  0.30 Hz
               GB  0
        PC 1.00
14 13 12 11 10 9 8 7 6 5 4 3 2 1 0 ppm   
 1. 00
 
   
0.9
40
.9
90
.8
81
.1
21
.3
41
.0
60
.9
80
.9
1 
  
 
 
       
 
COMPOUND  A2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13 12 11 10 9 8  7 6 5 4 3 2 1 0 ppm 
     1.0
0 
0.
57
1.
13
 
2.
12
 
 0 . 7 7       
 
Current Data Parameters 
NAME Feb07−2014
EXPNO 27
PROCNO 1
F2 − Acquisition Parameters
Date_ 20140207
Time 4.52
INSTRUM spect
PROBHD 5 mm PABBO BB− 
PULPROG zg30
TD 32768
SOLVENT DMSO
NS 32
DS 2
SWH 10330.578 Hz
FIDRES 0.315264 Hz
AQ 1.5860212 sec
RG 203
DW 48.400 usec
DE 6.50 usec
TE 299.3 K
D1 1.00000000 sec
TD0 1 
======== CHANNEL f1 ========
NUC1 1H
P1 10.65 usec
PL1 0.00 dB
PL1W 23.53637505 W
SFO1 500.1330885 MHz 
F2 − Processing parameters 
SI 32768
SF 500.1300000 MHz
WDW EM
SSB 0
LB 0.30 Hz
GB 0
PC 1.00
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COMPOUND  A3  Current Data Parameters 
NAME Feb07−2014
EXPNO 21
PROCNO 1
F2 − Acquisition Parameters
Date_ 20140207
Time 13.02
INSTRUM spect
PROBHD 5 mm PABBO BB−
PULPROG zg30
TD 32768
SOLVENT DMSO
NS 32
DS 2
SWH 10330.578 Hz
FIDRES 0.315264 Hz
AQ 1.5860212 sec
RG 114
DW 48.400 usec
DE 6.50 usec
TE 300.2 K
D1 1.00000000 sec
TD0 1 
======== CHANNEL f1 ========
NUC1 1H
P1 10.65 usec
PL1 0.00 dB
PL1W 23.53637505 W
SFO1 500.1330885 MHz 
F2 − Processing parameters 
SI 32768
SF 500.1300043 MHz
WDW EM
SSB 0
LB 0.30 Hz
GB 0
PC 1.00 
13 12 11 10 9 8 7 6 5 4 3 2 1 0 ppm 
      1.00
1.0
3   1.0 2      
 
 
 
COMPOUND  A4  Current Data Parameters 
NAME Feb07−2014
EXPNO 27
PROCNO 1
F2 − Acquisition Parameters
Date_ 20140207
Time 15.28
INSTRUM spect
PROBHD 5 mm PABBO BB−
PULPROG zg30
TD 32768
SOLVENT DMSO
NS 32
DS 2
SWH 10330.578 Hz
FIDRES 0.315264 Hz
AQ 1.5860212 sec
RG 181
DW 48.400 usec
DE 6.50 usec
TE 300.5 K
D1 1.00000000 sec
TD0 1 
======== CHANNEL f1 ========
NUC1 1H
P1 10.65 usec
PL1 0.00 dB
PL1W 23.53637505 W
SFO1 500.1330885 MHz 
F2 − Processing parameters 
SI 32768
SF 500.1300042 MHz
WDW EM
SSB 0
LB 0.30 Hz
GB 0
PC 1.00
 
 
 
13 12 11 10 9 8 7 6 5 4 3 2 1 0 ppm 
      1.00
1.0
3  1.0
3 
  
0.
0
8 
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COMPOUND   A5   Current Data Parameters 
NAME Feb07−2014
EXPNO 29
PROCNO 1
F2 − Acquisition Parameters
Date_ 20140207
Time 16.17
INSTRUM spect
PROBHD 5 mm PABBO BB−
PULPROG zg30
TD 32768
SOLVENT DMSO
NS 32
DS 2
SWH 10330.578 Hz
FIDRES 0.315264 Hz
AQ 1.5860212 sec
RG 181
DW 48.400 usec
DE 6.50 usec
TE 300.6 K
D1 1.00000000 sec
TD0 1 
======== CHANNEL f1 ========
NUC1 1H
P1 10.65 usec
PL1 0.00 dB
PL1W 23.53637505 W
SFO1 500.1330885 MHz 
F2 − Processing parameters 
SI 32768
SF 500.1300000 MHz
WDW EM
SSB 0
LB 0.30 Hz
GB 0
PC 1.00
 
 
 
 
 
14 13 12 11 10 9 8 7 6 5 4 3 2 1 0 ppm 
  0. 75
 
 0.
04
 
 
0.
0
8 
1.0
01
.11
 
  1.06
0.1
6 
 
0.
2
1  
   
 
 
 
COMPOUND   A6  Current Data Parameters 
NAME Feb07−2014
EXPNO 23
PROCNO 1
F2 − Acquisition Parameters
Date_ 20140207
Time 03.51
INSTRUM spect
PROBHD 5 mm PABBO BB−
PULPROG zg30
TD 32768
SOLVENT DMSO
NS 32
DS 2
SWH 10330.578 Hz
FIDRES 0.315264 Hz
AQ 1.5860212 sec
RG 203
DW 48.400 usec
DE 6.50 usec
TE 300.3 K
D1 1.00000000 sec
TD0 1 
======== CHANNEL f1 ========
NUC1 1H
P1 10.65 usec
PL1 0.00 dB
PL1W 23.53637505 W
SFO1 500.1330885 MHz 
F2 − Processing parameters 
SI 32768
SF 500.1300000 MHz
WDW EM
SSB 0
LB 0.30 Hz
GB 0
PC 1.00
 
14 13 12 11 10 9 8 7 6 5 4 3 2 1 0 ppm 
 0.
79
 
  
0.
03
 
 
0.
08
0.
02
1.
00
0.
05
0.
99
 
  1.
02
 
0.
17
 
0.
14
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COMPOUND  A7            Current Data Parameters
               NAME  Feb08−2014
               EXPNO  27
        PROCNO 1
               F2 − Acquisition Parameters
               Date_  20140208
               Time  4.52
               INSTRUM spect
               PROBHD 5 mm PABBO BB−
               PULPROG zg30
        TD 32768
               SOLVENT DMSO
        NS 32
        DS 2
               SWH  10330.578 Hz
        FIDRES 0.315264 Hz
               AQ  1.5860212 sec
        RG 203
               DW  48.400 usec
        DE 6.50 usec
               TE  299.3 K
        D1 1.00000000 sec
               TD0  1
               ======== CHANNEL f1 ========
               NUC1  1H
               P1  10.65 usec
               PL1  0.00 dB
               PL1W  23.53637505 W
        SFO1 500.1330885 MHz
               F2 − Processing parameters
               SI  32768
               SF 500.1300000 MHz
               WDW  EM
               SSB  0
               LB  0.30 Hz
               GB  0
        PC 1.00
13 12 11 10 9 8  7 6 5 4 3 2 1 0 ppm   
     
1.
0
0  
0.5
71
.13
 
2.
12
 
0.
77
 
         
 
 
COMPOUND  A8           Current Data Parameters
               NAME  Feb08−2014
               EXPNO  5
        PROCNO 1
               F2 − Acquisition Parameters
               Date_  20140208
               Time  21.49
               INSTRUM spect
               PROBHD 5 mm PABBO BB−
               PULPROG zg30
               TD  32768
               SOLVENT DMSO
               NS  32
               DS  2
               SWH  10330.578 Hz
               FIDRES  0.315264 Hz
               AQ  1.5860212 sec
               RG  203
               DW  48.400 usec
               DE  6.50 usec
               TE  300.0 K
               D1 1.00000000 sec
        TD0 1
               ======== CHANNEL f1 ========
               NUC1  1H
               P1  10.65 usec
               PL1  0.00 dB
               PL1W  23.53637505 W
        SFO1 500.1330885 MHz
               F2 − Processing parameters
               SI  32768
               SF 500.1300000 MHz
               WDW  EM
               SSB  0
               LB  0.30 Hz
               GB  0
        PC 1.00
13 12 11 10 9 8 7 6 5 4 3 2 1 0 ppm   
      1.000
.58
1.1
3 
1.2
11
.17
 
0.
61
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COMPOUND  A-9           Current Data Parameters
              NAME  Feb08−2014
              EXPNO  23
      PROCNO 1
      F2 − Acquisition Parameters
              Date_  20140208
              Time  4.36
              INSTRUM spect
              PROBHD 5 mm PABBO BB−
              PULPROG zg30
              TD  32768
              SOLVENT DMSO
              NS  32
              DS  2
              SWH  10330.578 Hz
              FIDRES  0.315264 Hz
              AQ  1.5860212 sec
              RG  203
              DW  48.400 usec
              DE  6.50 usec
              TE  299.3 K
              D1 1.00000000 sec
              TD0  1
              ======== CHANNEL f1 ========
              NUC1  1H
              P1  10.65 usec
              PL1  0.00 dB
              PL1W  23.53637505 W
      SFO1  500.1330885 MHz
              F2 − Processing parameters
              SI  32768
              SF 500.1300040 MHz
              WDW  EM
              SSB  0
              LB  0.30 Hz
              GB  0
      PC  1.00
13 12 11 10 9 8 7 6 5 4 3 2 1 0 ppm  
   1.
00
 
0.4
40
.83
 
 6.
52
 
2. 24
 
  
 
 
COMPOUND  A10           Current Data Parameters
               NAME  Feb08−2014
               EXPNO  11
        PROCNO 1
        F2 − Acquisition Parameters
               Date_  20140208
               Time  22.10
               INSTRUM spect
               PROBHD 5 mm PABBO BB−
               PULPROG zg30
               TD  32768
               SOLVENT DMSO
               NS  32
               DS  2
               SWH  10330.578 Hz
               FIDRES  0.315264 Hz
               AQ  1.5860212 sec
               RG  203
               DW  48.400 usec
               DE  6.50 usec
               TE  300.1 K
               D1 1.00000000 sec
        TD0 1
               ======== CHANNEL f1 ========
               NUC1  1H
               P1  10.65 usec
               PL1  0.00 dB
               PL1W  23.53637505 W
        SFO1 500.1330885 MHz
        F2 − Processing parameters
               SI  32768
               SF 500.1300035 MHz
               WDW  EM
               SSB  0
               LB  0.30 Hz
               GB  0
        PC 1.00
14 13 12 11 10 9 8 7 6 5 4 3 2 1 0 ppm 
 1. 00
 
   
0.9
40
.9
90
.8
81
.1
21
.3
41
.0
60
.9
80
.9
1 
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NMR  DATAS 
Table No. 7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                    
 
 
 
COMPOUND     TYPES OF  
     PROTON 
OBSERVEDVALUE 
        in PPM    
 
            A1 
S,15H ArH 
M,2H CH 
 8.8 
7.7 
 
A2 
S,15H ArH 
S, 1H,NH  
8.1 
2.1 
A3 S, 15H ArH 
S, 10H ArH 
7.1 
                 7.7 
A4 S,15H ArH 
S,2H CH 
7.0 
                 7.5 
A5 S, 10H ArH 
S,N-CH3 
7.6 
                 4.3 
A6 S,15H ArH 
M,2H CH 
7.4 
                 8.0 
A7 S,15H CH 
S, 1H ,NH 
7.1 
2.1 
A8 S, 15H ArH 
S,10H  ArH 
7.3 
                7.9 
A9 S,15H ArH 
S, 2H CH 
7.8 
9.1 
A10 S,15H ArH 
S,N-CH3 
8.9 
 6.9 
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MASS SPECTROSCOPY 
                      COMPOUND    A1 
 
 
COMPOUND  A2 
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COMPOUND   A3 
 
 
COMPOUND    A4 
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COMPOUND   A5 
 
 
COMPOUND   A6 
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COMPOUND  A7 
 
 
COMPOUND  A8 
 
 
 
 
Chapter VIII                                                                                 Spectral data  
 
Department of Pharmaceutical Chemistry, MMC, Madurai. Page 98 
 
COMPOUND    A9 
 
 
COMPOUND   A10 
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MASS SPECTRAL DATAS 
Table.No:8 
                 COMPOUND  
OBSERVED PEAK 
            A1        361.4 
 
            A2        380.4 
 
            A3         463.5   
 
            A4         365.4 
 
            A5          339.4 
 
            A6          395.8          
 
            A7          414.9 
 
            A8           498 
 
            A9           399.9 
 
            A10           373.8 
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BIOLOGICAL EVALUATION 
IN VITRO- ANTIBACTERIAL ACTIVITY(21,25,42,51-53) 
TEST CONCENTRATION: 
 100µg/ml 
 200µg/ml 
ORGANISM USED: 
 Bacillus subtilis 
 Klebsiella pneumonia 
SOLVENT USED:          
 DMSO 
STANDARD DRUG: 
 Amikacin 
  MEDIA PREPARATION: 
  MULLER- HINTON AGAR MEDIUM: 
INGREDIENTS: 
Beef infusion   -  300ml 
Casein Hydrolysate  -  17.5g 
Starch    -  1.5g 
Agar      -  10g 
Distilled water   -    1litr 
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PROCEDURE: 
Emulsify the starch in a small amount of cold water, pour into the beef infusion and 
add the casein hydrolysate and the agar. Make up the volume to 1litre with distilled water. 
Dissolve the constituents by heating gently at 100°C with agitation. Filter if necessary. Adjust 
the pH to 7.4.Dispense in screw-capped bottles and sterilized by autoclaving at 121°C for 
20minutes and pour plates. 
 
PREPARATION OF ANTIBACTERIAL SOLUTION: 
All the test compound were dissolved in dimethyl sulfoxide and taken at two 
concentration for testing antibacterial activity. The compounds were diffuse into the medium 
produced a concentration gradient. After the incubation period, the zone of inhibition were 
measured in mm. 
 
 EXPERIMENTAL PROCEDURE: 
The plates were inoculated by dipping a sterile swab into inoculums. The inoculation 
was dried at room temperature in aseptic condition. Ditch the bore in plate, to this bore add 
prepared antibacterial solution. These plates were placed in an incubator at 37°C within a few 
minutes of preparation. After 48 hours of incubation the diameter of zone of inhibition was 
measured and reading observed in millimeter. 
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ZONE OF INHIBITION OF SYNTHESIZED COMPOUNDS AGAINST  BACTERIA 
Table.No:9 
SAMPLE 
BACILLUS KLEBSIELLA 
100µg/ml 200µg/ml 100µg/ml 200µg/ml 
A1 
 
R 9 R R 
A2 
 
6 17 R 12 
A3 
 
10 15 R 10 
A4 
 
8 14 R 8 
A5 
 
11 16 R 12 
A6 
 
R 9 R R 
A7 
 
15 21 8 17 
A8 
 
R 12 R 9 
A9 
 
R 14 R R 
A10 
 
7 16 R 6 
CONTROL 
 
R R R R 
STD 
 
17 17 20 20 
 
ALL MEASUREMENT IN{ MMS } 
R = RESISTANT 
CONTROL= DMSO                 
STD = AMIKACIN 
BACIL
BACIL
 
LUS SU
LUS SU
A
BTILIS 
BTILIS 
NTIBAC
–A3, A4  
– A7, A8 
TERIAL
               
    
          BA
    
 ACTIV
  BACILL
SCILLU
ITY 
US SUB
S SUBTI
TILIS –A
LIS - CO
1, A2     
NTROL 
 
                
                
 
                                   ANTIBACTERIAL ACTIVIT 
KLEBSIELLA PNEUMONIA –A1, A2 KLEBSIELLA PNEUMONIA–A3, A4  
         
KLEBSIELLA PNEUMONIA –A7,A8         KLEBSIELLA – CONTROL
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ANTIFUNGAL ACTIVITY(21,25,42,51-53) 
TEST CONCENTRATION: 
 100µg/ml 
 200µg/ml 
ORGANISM USED: 
 Candida Albicans 
 Aspergillus Niger 
SOLVENT USED:          
 DMSO 
STANDARD DRUG: 
 Ketokonazole 
MEDIA PREPARATION: 
POTATO DEXTROSE AGAR MEDIUM 
INGREDIENTS: 
 Potato    - 200g 
Dextrose    - 20g  
Agar     - 20g 
Water    - 1litre 
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PROCEDURE: 
Scrub but do not peel the potatoes and cut into 12mm cubes. Boil 200g potato in 1litre 
of water for 60 minutes. Squeeze as much of the pulp as possible through a fine sieve. Add 
agar and boil till dissolved. Add dextrose and make up to 1litre. Dispense in required 
amounts taking care to keep solids in suspension. Autoclave at 115°C and pour 
approximately 20ml amounts into petri dishes.  
  
PREPARATION OF ANTI FUNGAL SOLUTION: 
All the test compound were dissolved in dimethyl sulfoxide and taken at two 
concentration for testing antibacterial activity. The compounds were diffuse into the medium 
produced a concentration gradient. After the incubation period, the zone of inhibition were 
measured in mm. 
 
EXPERIMENTAL PROCEDURE: 
The plates were inoculated by dipping a sterile swab into inoculums. The inoculation 
was dried at room temperature in aseptic condition. Ditch the bore in plate, to this bore add 
prepared antibacterial solution. These plates were placed in an incubator at 22°C within a few 
minutes of preparation. After 7 days of incubation the diameter of zone of inhibition was 
measured and reading observed in millimeter. 
 
 
 
 
 
ANTIFUNGAL ACTIVITY 
CANDIDA ALBICANS – A7, A8                  CANDIDA ALBICANS – A1, A2 
         
CANDIDA ALBICANS – A9,A10   CANDIDA ALBICANS – CONTROL 
 
          
 
ANTIFUNGAL ACTIVITY 
    ASPERGILLUS NIGER A9, A10               ASPERGILLUS NIGER A7, A8           
                                             
 
                      ASPERGILLUS NIGER - CONTROL           
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ZONE OFINHIBITION OF SYNTHESIZED COMPOUNDS AGAINST FUNGI 
Table.No:10 
SAMPLE 
CANDIDA ASPERGILLUS 
100µg/ml 200µg/ml 100µg/ml 200µg/ml 
A1 3 7 R R 
A2 R 6 R R 
A3 R 10 R R 
A4 R 8 R R 
A5 5 11 R R 
A6 R 9 R R 
A7 R 7 R 9 
A8 5 9 R R 
A9 5 12 R 6 
A10 5 12 R 8 
CONTROL R R R R 
STD 21 21 18 18 
 
ALL MEASUREMENT IN{ MMS } 
R = RESISTANT 
 CONTROL = DMSO 
STD = KETOKONAZOLE 
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ZONE OF MAXIMUM INHIBITION OFSYNTHESIZED 
COMPOUND   A1- A10 AGAINST MICROBIAL AGENTS 
Table.No:11 
ORGANISM BACTERIA FUNGI 
COMPOUNDS BACILLUS KLEBSIELLA CANDIDA 
ASPERGILLUS
 
A1 
 
9 - 7 - 
A2 
 
17 12 6 - 
A3 
 
15 10 10 - 
A4 
 
14 8 8 - 
A5 
 
16 12 11 - 
A6 
 
9 - 9 - 
A7 
 
21 17 7 9 
A8 
 
12 9 9 - 
A9 
 
14 - 12 6 
A10 
 
16 6 12 8 
STD 
 
20 17 21 18 
Zone of inhibition in mm 
STD: BACTERIA – AMIKACIN, FUNGI  -  KETAKONAZOLE 
INVITRO - ANTI MICROBIAL ACTIVITY 
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IN VITRO-ANTIOXIDANT ACTIVITY(54,56,57) 
PRINCIPLE: 
This is spectrophotometric method and is based on the principle that increases in 
absorbance of the reaction mixture as concentration increase showing an increased 
antioxidant activity. The assay is based on the reduction of ferric in potassium ferric cyanide 
to potassium ferrocyanide by the sample and the subsequent formation of Prussian blue 
colour with ferric chloride. The absorbance of the blue complex is measured at 700nm. 
                  Potassium ferric cyanide  +Ferric chloride 
                                                      
Antioxidant
 
                Potassium ferrocyanide   +   ferrous chloride 
 
INSTRUMENTS: 
Shimadzu UV Visible spectroscopy  
Model 1800 
REAGENTS: 
1%Potassium ferric cyanide 
10% Trichloro acetic acid  
0.2M, pH 6.6 phosphate buffer 
0.1% ferric chloride 
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PROCEDURE:  
 About 0.5ml of various concentration of synthesized compound was mixed 
with 0.75ml phosphate buffer and 0.75ml of 1% potassium ferricyanide 
then mixture was incubated at 50°C for 20 minutes. 
 0.75ml of 1% trichloro acetic acid was added to the mixture, allowed to 
stand for 10 minutes. 
 The whole mixture was then centrifuged at 3000ppm for 10 minutes. 
 Finally 1.5ml of supernatant solution was removed and mixed with 1.5ml 
of distilled water  
 Then added 0.1ml of 0.1%ferric chloride solution and the absorbance was 
measured at 700nm in UV – Visible spectrophotometry. 
  Higher the absorbance observed in test mixture indicates the stronger 
reducing power of the test solution. 
 Ascorbic acid was used as standard and phosphate buffer used as blank 
solution. 
 The absorbance of the final reaction mixture of three parallel experiments 
was expressed as mean ± standard error of the mean. 
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IN VITRO -REDUCING POWER ASSAY 
Table.No:12 
 
                                     STD:  ASCORBIC ACID 
                                                      *Mean 3value±SEM 
 
 
 
 
 
COMPOUNDS/ 
CONCENTRATION 
ABSORBANCE*
    100µg/ml     200µg/ml   300µg/ml 
       A1  0.075±0.0032 0.12±0.0011 0.145±0.0011 
       A2  0.172±0.0030 0.238±0.0037 0.269±0.0055 
       A3 0.076±0.0020 0.111±0.0011 0.140±0.0026 
       A4 0.146±0.0011 0.207±0.002 0.231±0.0017 
       A5 0.163±0.0038 0.203±0.002 0.267±0.0024 
       A6 0.096±o.0008 0.145±0.002 0.285±0.003 
       A7 0.196±0.0017 0.285±0.0023 0.305±0.005 
       A8 0.102±0.0014 0.160±0.002 0.247±0.0011 
       A9 0.161±0.0024 0.257±0.0024 0.326±0.0017 
       A10 0.207±0.00024 0.274±0.0011 0.348±0.0015 
       STD 0.165±0.0014 0.368±0.0025 0.565±0.0026 
IN VITRO - ANTIOXIDANT ACTIVITY 
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IN VITRO - ANTI ARTHRITIC ACTIVITY(27,38,40,56) 
Phosphate buffer saline pH 6.3: 
Dissolve 8gm of sodium chloride 0.2gm of potassium chloride 1.44gm of disodium 
hydrogen phosphate 0.24 gm in potassium dihydrogen phosphate in 800 ml of distilled water.  
The pH was adjusted to 6.3 using 1N HCl make up the volume to 1000ml with distilled 
water. 
METHOD: 
1) Test solution (0.5ml) consists of 0.45ml of bovine serum (5% w/v 
aqueous solution)and 0.05ml of test solution various concentration. 
2) Test control solution0.5ml consists of 0.45ml of bovine serum albumin 
and 0.05ml of water.  
3) Product control 0.5ml consists of 0.45ml of water and 0.05ml of test 
solution. 
4) Standard solution 0.5ml consists of 0.45ml of bovine serum albumin 
and 0.05ml of diclofenac sodium of various concentrations. 
5) Various concentration (100,250,500µg/ml) of test drug and standard drug 
diclofenac sodium (100,250,500µg/ml)were taken respectively. 
6) All the above solution were adjusted to pH 6.3 using 1N HCl. 
7) The sample were incubated at 37°C for 20 minutes. Temperature was 
increased to keep the samples at 57°C for 3 minutes. 
8) After cooling, add 2.5ml of phosphate buffer to the above solution. 
9) The absorbance was measured using UV visible spectrophotometer at 
416nm.   
 Percentage inhibition= 100 – {optical density of test control – optical             
 Density of product control}                   x100  
Optical density of test solution 
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IN VITRO – ANTIARTHRITIC ACTIVITY 
Table.No:13 
 
 
 
                                              STD:  DICLOFENAC 
                                                                   *Mean 3value ±SEM 
 
 
 
 
 
COMPOUNDS/ 
CONCENTRATION 
                % INHIBITION*
100µg/ml 250µg/ml 500µg/ml 
           A1 41±0.54 62.9±0.52 72.8±0.46 
 
          A2 55±0.0.46 61.3±0.53 70.1±0.40 
 
          A3 58.8±0.61 60.9±0.52 70.7±0.25 
 
          A4 56.5±0.28 72.9±0.31 81±0.23 
 
          A5 57.3±0.35 67.2±0.43 78.3±0.35 
 
          A6 49.7±0.21 61±0.460 70.6±0.31 
 
          A7 67±0.401 74.1±0.25 82.2±0.33 
 
          A8 65.1±0.20 76.3±0.35 84.1±0.21 
 
          A9 64.5±0.26 70.7±0.25 82.1±0.20 
 
         A10 68.7±0.20 76.4±0.26 83.4±0.32 
 
         STD 60.7±0.53 72.3±0.40 86.2±0.43 
 
                   IN VITRO - ANTI ARTHRITIC ACTIVITY 
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IN VIVO - ANTIANGIOGENIC ACTVITY 
CHICKEN CHORIOALLANTOIC MEMBRANE (CAM) NEOVASCULARISATION 
MODEL IN THE FERTILIZED CHICKEN EGGS. 
 The in vivo anti-angiogenic effect of the test compound was investigated 
by CAM assay. 
 Fertilized chicken eggs of 5 days old were obtained from a local hatchery. 
 Albumin 5 ml was with drawn and the eggs were incubated horizontally 
to allow the CAM detachment of the shell. 
 The compound were dissolved in ethanol and prepared as methyl cellulose 
discs at the concentration of 50, 100µg/disc. Disc containing the vehicle 
alone (ethanol) were used as negative control. 
 A small window was made on the shell through which the disc were 
applied the CAM. 
 The window was closed back and sealed with a sterile surgical tap and the 
eggs were incubated for another 24 hrs.  
 The images of each treated CAM were captured under dissecting 
microscope. 
 The blood vessels in the disc application site were counted to calculate the 
percentage inhibition.     
 % inhibition=vessel number of CAM treated normal saline – vessel 
number of CAM treated synthesized compound / vessel number of CAM 
treated normal saline X 100 
Table.No.14 
 
COMPOUND
% INHIBITION 
50µg/ml 100µg/ml
A4 45.3 62.5 
A7 53.7 76.1 
      
IN VIVO – ANTI ANGIOGENESIS 
COMPOUND  A4(50µg/ml)                                  COMPOUND  A4(100µg/ml) 
 
 
COMPOUND   A7(50µg/ml)                                COMPOUND   A7(100µg/ml) 
 
                                                       CONTROL 
                           
 
RESULTS &  
                    DISCUSSION  
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Results and Discussion 
 The molecular design of synthesized compound were done by using different software. 
 The lipinskin rule was predicted for all synthesized compound using CHEMDOODLE. 
The results were shown in Table.No:1 
 The molecular formula,molecular weight and I.U.P.A.C name are predicted and shown in 
Table.No:2 
 The pecentage yield, melting point, solubility and appearance of the compound are 
determined and shown in Table.No;3 
 The purity of the compounds were checked by TLC and Rf value was calculated. The 
results are shown in Table.No:4 
 Elemental compostion were found and calculated in percentage and results obtained were 
shown in Table. No:5 
 The structure of the synthesized compounds were confirmed by IR spectraNMR spectra 
and Mass spectra. 
 IRspectra interpert value shown in Table.No:6 
 NMR specctra interpert value shown in Table.No:7 
 Mass spectra results are shown in Table.No.8 
 All synthesized compounds were screened for their invitro antimicrobial, antioxidant, anti 
arthritic  and in vivo anti angiogenesis activiy. 
 The antibacterial activity was performed against bacillus subtilis, klebsiella pneumonia. 
The zone of inhibition was performed by cup-plate method and results are obtained were 
measured in milimeter shown in Table.No:9 
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 The graphical representation compound were shown and compared with the standard 
Amikacin. 
 The antifungal activity was performed against candida albicans,aspegillus niger. The 
zone of inhibition was performed by cup-plate method and results are obtained were 
measured in milimeter shown in Table.No:10 
 The graphical representation compound were shown and compared with the standard 
Ketakonazole.  
 The maximum zone of inhibition of synthesized compound against antimicrobial activity 
shown in Table.No:11 
 All synthesized compound were tested for invitro anti oxidant activity by reducing power 
assay method in different concentration and compared with the standard Ascorbic acid. 
The result are shown in Table.No:12 
 All of the newly obtained compound were tested for invitro anti arthritic activity by 
protein denaturated method in different concentration and compared with the standard 
Diclofenac. The results are shown in Table.No:13 
 The synthesized compounds of A4 and  A7 were screened for in vivo anti angiogenesis 
activity using chorioallantoic membrane neovascularisation model in the fertilized 
chicken eggs. The results are shown in Table.No:14 
SUMMARY &  
                  CONCLUSION 
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SUMMARY AND CONCLUSION 
 Preliminary screening of novel 2,4,5 triphenyl derivative was done by using 
chemdoodle and molinspiration software. 
 The synthesized compounds were found to be identified by TLC. 
 All synthesized compounds were purified and characterized by the IR,NMR and 
MASS spectrals datas. 
 The spectral datas were coinciding with the structure of synthesized compounds. 
 All the relevant peaks were identified in all the spectras. 
 The synthesized compounds were screened for invitro antimicrobial, anti 
oxidant, antiarthritic activity and in vivo antiangiogenesis activity. 
 In vitro Antimicrobial activity: 
Thecompound A7 shows potent antibacterial activity against bacillus 
subtilis and Klebsiella pneumonia compared to standard Amikacin.  
The compound A9& A10 shows moderate antifungal activity against 
candida albicans compared to standard ketokonazole.The compound A7 
minimum inhibition of antifungal activity against aspergillus niger compared to 
standard Ketokonazole. 
 In vitro Antioxidant acivity: 
The following compounds A7,A9, A10 are reducing the free radicals and 
prevent the tissue damage and producing best anti oxidant properties which is 
evaluated by reducing power assay. When it is compared to standard like 
Ascorbic acid these are shows lesser activity. 
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 In vitro Antiarthritic activity: 
Synthesized compounds like A4,A7,A8,A9,A10 are control the risk of 
arthritic. It was controlled by protein denaturation. Through this studies 
compound A8 shows excellent anti arthritic activity compared to the standard 
Diclofenac. 
In future we can carry out the in vivo studies in these compound 
ultimately we should confirm the anti arthritic activity. 
 In vivo anti angiogenesis activity: 
Compound A4,A7 are block blood vessels formation in the chorioallantoic 
membrane. It was identified the neovascularisation model in the fertilized 
chicken eggs. It can be acknowledge by photo copies of chrioallantoic 
membrane.  
In future if it is possible to alter the compound by substitution. While it 
expose the good anti canceractivity also. 
 Compound A7[ 5-(4-chlorophenyl)2,4, Diphenyl -1H imidazole 1-yl 
piperzine] having in vitro Anti microbial, Antioxidant, Antiarthritic and in 
vivo Antiangiogenesis activity, As per my knowledge I conclude that 
compound A7[ 5-(4-chlorophenyl)2,4, Diphenyl -1H imidazole 1-yl 
piperzine] is the best compound compare than other than nine 
compounds. 
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